Abstract
Antiandrogen withdrawal response is an increasingly recognized entity in patients with metastatic prostate cancer. To our knowledge, there have been no reports describing a durable radiologic improvement along with prostate-specific antigen (PSA) with discontinuation of the antiandrogen agent bicalutamide. We report a case in which a dramatic decline of serum PSA levels associated with a dramatic improvement in radiologic disease was achieved with bicalutamide discontinuation.
| Original language | English (US) |
|---|---|
| Article number | 21 |
| Journal | Journal of Hematology and Oncology |
| Volume | 1 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2008 |
All Science Journal Classification (ASJC) codes
- Hematology
- Molecular Biology
- Oncology
- Cancer Research